Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada

New England Journal of Medicine

Volumn 341, Issue 4, 1999, Pages 233-229

  Chen, Danny K ^a   McGeer, Allison ^a,b,c   De Azavedo, Joyce C ^a,b,c   Low, Donald E ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CANADA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CANADA; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 0033595136     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199907223410403     Document Type: Article

References (52)

1. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27:764-70.
2. Rahal K, Wang F, Schindler J, et al. Reports on surveillance of antimicrobial resistance in individual countries. Clin Infect Dis 1997;24:Suppl 1: S169-S175.
3. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RE The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pncumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-93.
4. Gruneberg RN, Felmingham D. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996;25:169-81.
5. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995. results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40: 1208-13.
6. Lee BL, Kimbrough RC, Jones SR, Chaisson RE, Mills J. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520-1.
7. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998;27:730-8.
8. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management: the Infectious Diseases Society of America. Clin Infect Dis 1998;26:811-38.
9. Campbell GD Jr. Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia. Chest 1999;115:Suppl 3:14S-18S.
10. Simor AE, Louie M, Low DE. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae: Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother 1996;40:2190-3.
11. Richard MP, Aguado AG, Mattina R, Marre R. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study: SPAR Study Group: Surveillance Programme of Antibiotic Resistance. J Antimicrob Chemother 1998;41:207-14.
12. Barry AL, Fuchs PC, Allen SD, Brown SD, Jorgensen JH, Tenover FC. In-vitro susceptibility of Streptococcus pneumoniae to the d-and l-isomers of ofloxacin: interpretive criteria and quality control limits. J Antimicrob Chemother 1996;37:365-9.
13. Ballow CH, Jones RN, Johnson DM, Deinhart JA, Schentag JJ. Comparative in vitro assessment of sparfloxadn activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA: SPAR Study Group. Diagn Microbiol Infect Dis 1997;29:173-86.
14. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996;40:2760-4.
15. Hooper DC. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis 1998;27:Suppl 1:S54-S63.
16. Tankovic J, Perichon B, Duval J, Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother 1996;40:2505-10.
17. Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996;40:2252-7.
18. Performance standards for antimicrobial susceptibility testing: eighth informational supplement. NCCLS document M100-SB. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1998.
19. Lovgren M, Spika JS, Talbot JA. Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. CMAJ 1998;158:327-31.
20. Murray BE, Singh KV, Heath JD, Sharma BR, Weinstock GM. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J Clin Microbiol 1990;28:2059-63. Erratum, J Clin Microbiol 1991;29:418.]
21. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.
22. Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40:2321-6.
23. Sreedharan S, Peterson LR, Fisher LM. Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1991;35:2151-4.
24. Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 1996;313:387-91.
25. Seppälä H, Nissinen A, Järvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992;326:292-7.
26. Brook I, Gober AE. Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. Clin Infect Dis 1996;22:143-5.
27. Reichler MR, Rakovsky J, Sobotova A, et al. Multiple antimicrobial resistance of pneumococci in children with otitis media, bacteremia, and meningitis in Slovakia. J Infect Dis 1995;171:1491-6.
28. Duchin JS, Breiman RF, Diamond A, et al. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Pediatr Infect Dis J 1995;14:745-50.
29. Wang EEL, Kellner JD, Arnold S. Antibiotic-resistant Streptococcus pneumoniae: implications for medical practice. Can Fam Physician 1998;44: 1881-8.
30. Hall LM. Application of molecular typing to the epidemiology of Streptococcus pneumoniae. J Clin Pathol 1998;51:270-4.
31. Kristinsson KG, Hjalmarsdottir MA, Steingrimsson O. Increasing penicillin resistance in pneumococci in Iceland. Lancet 1992;339:1606-7.
32. Soares S, Kristinsson KG, Musser JM, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis 1993;168:158-63.
33. Munoz R, Coffey TJ, Daniels M, et al. Intercontinental spread of a multiresistant clone of scrotype 23F Streptococcus pneumoniae. J Infect Dis 1991;164:302-6.
34. Stephenson J. Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria. JAMA 1996;275:175.
35. Coffey TJ, Berron S, Daniels M, et al. Multiply antibiotic-resistant Streptococcus pneumoniae recovered from Spanish hospitals (1988-1994): novel major clones of serotypes 14, 19F and 15F. Microbiology 1996;142:2747-57.
36. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-5.
37. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season: the Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997;29:249-57.
38. Fuchs PC, Barry AL, Brown SD. Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, of loxacin and levofloxacin. J Antimicrob Chemother 1997;39:671-2.
39. Goldstein FW, Acar JF, Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study: the Alexander Project Collaborative Group. J Antimicrob Chemother 1996;38:Suppl A:71-84.
40. Goldsmith CE, Moore JE, Murphy PG, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J Antimicrob Chemother 1998;41:420-1.
41. Goldsmith CE, Moore JE, Murphy PG. Pneumococcal resistance in the UK. J Antimicrob Chemothcr 1997;40:Suppl A:11-8.
42. Kam KM, Lucy KY, Fung SM, Yiu PP, Harden TJ, Cheung MM. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1995;39:2667-70.
43. Yoshida R, Kaku M, Kohno S, et al. Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrob Agents Chemother 1995;39:1196-8.
44. Setchanova L. Clinical isolates and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Hospital for Infectious Diseases, Sofia, Bulgaria, 1991-1993. Microb Drug Resist 1995;1:79-84.
45. Marchese A, Debbia EA, Arvigo A, Pesce A, Schito GC. Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. J Antimicrob Chemother 1995;36:833-7.
46. Mittermayer H, Jebelean C, Binder L, Haditsch M, Watschinger R. Antibiotic susceptibility of pneumococci isolated in Austria over a four-year period. Eur J Clin Microbiol Infect Dis 1996;15:817-20.
47. Douidar SM, Snodgrass WR. Potential role of fluoroquinolones in pediatric infections. Rev Infect Dis 1989;11:878-89.
48. Wise R, Andrews JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother 1997;40:Suppl A:27-30.
49. Wise R, Brenwald N, Gill M, Fraise A. Streptococcus pneumoniae resistance to fluoroquinolones. Lancet 1996;348:1660.
50. Hooper DC. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med 1998;129:908-10.
51. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A 1997;94:13991-6.
52. Dalhoff A, Heidtmann M, Obertegger S, Hesse D. Lack of in vivo emergence of resistance against Bay 12-8039 in Staph. aureas and Strep. pneumoniae. In: Program and abstracts of the Eighth International Congress on Infectious Diseases, Boston, May 15-18, 1998:124. abstract.